JAZZ
Jazz Pharmaceuticals PLC
NASDAQ: JAZZ · HEALTHCARE · BIOTECHNOLOGY
$199.92
-1.99% today
Updated 2026-04-29
Market cap
$12.54B
P/E ratio
—
P/S ratio
2.94x
EPS (TTM)
$-5.83
Dividend yield
—
52W range
$98 – $207
Volume
1.0M
WallStSmart proprietary scores
55
out of 100
Grade: C+
Hold
Investment rating
5.3
Growth
C+4.8
Quality
C5.0
Profitability
C+7.7
Valuation
B+3/9
Piotroski F-Score
Weak
1.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$225.53
+12.81%
12-Month target
—
—
Intrinsic (DCF)
$381.38
Margin of safety
+56.41%
5 Strong Buy9 Buy2 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $296.79M — positive
+ Revenue growth 10.10% QoQ
+ 56.41% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 1.04 — distress zone
- Thin margins at -8.35%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $3.66B | $3.83B | $4.07B | $4.27B | $4.27B |
| Net income | $-224.06M | $414.83M | $560.12M | $-356.15M | $203.45M |
| EPS | — | — | — | — | $-5.83 |
| Free cash flow | $773.78M | $1.07B | $1.35B | $1.30B | $296.79M |
| Profit margin | -6.12% | 10.82% | 13.77% | -8.35% | -8.35% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | COZADD, BRUCE C | Sale | 3,684 | $190.22 |
| 2026-04-01 | COZADD, BRUCE C | Sale | 2,292 | $190.94 |
| 2026-04-01 | COZADD, BRUCE C | Sale | 24 | $191.74 |
Peer comparison
Smart narrative
Jazz Pharmaceuticals PLC trades at $199.92. Our Smart Value Score of 55/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.04, it sits in the distress. TTM revenue stands at $4.27B. with profit margins at -8.35%. Our DCF model estimates intrinsic value at $381.38.
Frequently asked questions
What is Jazz Pharmaceuticals PLC's stock price?
Jazz Pharmaceuticals PLC (JAZZ) trades at $199.92.
Is Jazz Pharmaceuticals PLC overvalued?
Smart Value Score 55/100 (Grade C+, Hold). DCF value $381.38.
What is the price target of Jazz Pharmaceuticals PLC (JAZZ)?
The analyst target price is $225.53, representing +12.8% upside from the current price of $199.92.
What is the intrinsic value of Jazz Pharmaceuticals PLC (JAZZ)?
Based on our DCF model, intrinsic value is $381.38, a +56.4% margin of safety versus $199.92.
What is Jazz Pharmaceuticals PLC's revenue?
TTM revenue is $4.27B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
1.04 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.94x
ROE-8.47%
Beta0.23
50D MA$188.62
200D MA$155.51
Shares out0.06B
Float0.06B
Short ratio—
Avg volume1.0M
Performance
1 week-0.02%
1 month+5.75%
3 months+21.92%
YTD+17.60%
1 year—
3 years—
5 years—